Study identifier:D9341C00001
ClinicalTrials.gov identifier:NCT06194461
EudraCT identifier:N/A
CTIS identifier:2024-511602-23-00
A LOng-term Follow-up Master Protocol for Participants who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
Hepatocellular Carcinoma
Phase 1/2
No
-
All
64
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Mar 2025 by AstraZeneca
AstraZeneca
-
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
This is a multi-centre and multinational basket study that will monitor the long-term safety and tolerability of cell or gene therapies in participants that have taken part in other AstraZeneca cell or gene therapy studies for up to 15 years.
Location
Location
Duarte, CA, United States, 91010
Location
San Francisco, CA, United States, 94143
Location
Westwood, KS, United States, 66205
Location
Hackensack, NJ, United States, 07601
Location
Pittsburgh, PA, United States, 15237
Location
Columbus, OH, United States, 43210
Location
Philadelphia, PA, United States, 19104
Location
Portland, OR, United States, 97239
Arms | Assigned Interventions |
---|---|
Experimental: AZD5851 Follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884 | Biological/Vaccine: AZD5851 Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884. |
AZD0754 Follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729 | Biological/Vaccine: AZD0754 Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.